Advagene Biopharma completed its board of directors election at the shareholders’ meeting on the 3rd. Following the meeting, the board appointed Huang Yi-xu as the new chairman. CEO Hsu You-shen stated that the company will fully advance the Phase II clinical trial of its nasal spray treatment for severe eosinophilic asthma, with completion expected in 2026.
In addition, for acute infectious disease products such as the nasal spray immunotherapy for COVID-19 and the enhanced influenza vaccine for the elderly, the company will adopt an external licensing or partnership clinical development strategy with major pharmaceutical firms.
To expand its business scope, Advagene will also enter the dermatological medical formulation field this year, actively developing second-pillar products targeting skin immune diseases including atopic dermatitis, eczema, and psoriasis.
New chairman Huang Yi-xu is the largest individual shareholder of Advagene. After 24 years of service at a major U.S. biopharmaceutical company, he returned to Taiwan to found Mycenax Biotech and later served as the CEO of the biopharmaceutical manufacturing plant at the National Health Research Institutes.
At the shareholders’ meeting on the 3rd, nine directors were elected: Huang Yi-xu; Hsu You-shen and Xiao Qin-yi (representing Taiwan Mask); Chen Bi-rong; Wu Hao-qun; Global Investment Holdings (corporate director); and independent directors Chen Gui-heng, Huang Ya-hui, and Zhu Wei-ling.
Hsu You-shen said that the Phase IIa clinical trial of the nasal spray for severe eosinophilic asthma achieved positive and encouraging results in 2024 and was presented at the American Academy of Allergy, Asthma & Immunology conference at the end of February 2025. Given the large market for severe asthma treatments, patient recruitment for the Phase IIa trial ended early in February, and the company has begun submitting its Investigational New Drug (IND) application for the formal Phase II trial to Taiwan’s Ministry of Health and Welfare. The planned multicenter clinical trial will recruit 120 subjects across 10 medical centers in Taiwan and is expected to be completed within two years.
Hsu also pointed out that Advagene’s proprietary LTh (αK) immunomodulation technology platform is a safe and effective immunomodulator and vaccine adjuvant. It can be applied in treating respiratory autoimmune allergic asthma, respiratory viral infections, and nasal spray immunizations. The company holds international patents for this platform in 11 major countries and regions.
The company’s product pipeline developed based on this platform includes: respiratory allergy and asthma treatments that have completed Phase IIa clinical trials with significant efficacy; nasal spray influenza vaccines with completed Phase II trials showing significant effects; COVID-19 immunotherapy drugs that have completed Phase IIa trials with notable results; and treatments for other respiratory diseases.
Resource: 昱厚董事改選 黃一旭任新董座
